Wire · opportunities
FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 July 2026 · Fusion42 review
An FDA advisory committee voted 8-6 to add BPC-157, a peptide currently available only on grey and black markets, to the compounding drug list — a non-binding decision that would allow legal prescription access in the US despite minimal human clinical trial data on safety or efficacy.
This Wire brief sits within Fusion42's coverage of Digital Health, and 9 sources have reported it between 23 Jul 2026 and 28 Jul 2026.
◆ ◆ The Wire takeaway
If you're building a telemedicine or direct-to-consumer health platform, the peptide market just shifted from grey-market arbitrage to regulated legitimacy — your distribution model and liability footprint change this week. The gap between what's being sold online and what the FDA will now allow to be compounded is where you can defensibly build a compliant brand.
◆ Coverage
9 sources · first reported 23 Jul 2026 · latest 28 Jul 2026
◆ Related on Wire
◆ Topics